Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
161Tb-PSMA-1 in Metastatic Clear Cell Renal Cell Carcinoma
NCT07828249Phase 1Not yet recruiting
- Sponsor
- Centre Léon Bérard
- Start
- Nov 2026
- Primary completion
- Nov 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of terbium (161Tb) zadavotide guraxetan in clear cell renal cell carcinoma (ccRCC), sponsored by Centre Léon Bérard. Primary endpoint: Dose-Limiting Toxicities at 6 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
terbium (161Tb) zadavotide guraxetan
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07828249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07828249.